摘要
目的探讨异环磷酰胺联合多西紫杉醇+顺铂(DP)方案治疗复发难治性骨肉瘤的效果及安全性。方法根据治疗方式将98例复发难治性骨肉瘤患者分为一般化疗组和异环磷酰胺组,每组49例,一般化疗组患者给予DP方案化疗,异环磷酰胺组患者在此基础上联合异环磷酰胺化疗。比较两组患者肿瘤标志物[肿瘤特异性生长因子(TSGF)、血管内皮生长因子(VEGF)、大鼠肉瘤癌基因(RAS)及erb-b2受体酪氨酸激酶3(ERBB3)]、肢体功能、睡眠质量、临床疗效和不良反应发生情况。结果治疗后,两组患者TSGF、VEGF、RAS、ERBB3水平均低于本组治疗前(P﹤0.05),且异环磷酰胺组患者TSGF、VEGF、RAS、ERBB3水平均低于一般化疗组(P﹤0.05)。治疗后,两组患者的Harris量表评分均明显高于本组治疗前(P﹤0.01),匹兹堡睡眠质量指数(PSQI)均明显低于本组治疗前(P﹤0.01);且异环磷酰胺组患者的Harris量表评分明显高于一般化疗组(P﹤0.01),PSQI评分明显低于一般化疗组(P﹤0.01)。异环磷酰胺组患者的治疗有效率为46.94%,高于一般化疗组患者的22.45%(P﹤0.05),不良反应总发生率为6.12%,明显低于一般化疗组患者的28.57%(P﹤0.01)。结论异环磷酰胺联合DP方案治疗复发难治性骨肉瘤,可有效抑制肿瘤细胞发展,控制病情,促进肢体功能恢复,改善睡眠质量。
Objective To explore the efficacy and safety of ifosfamide combined with docetaxel+cisplatin(DP)regi-men in the treatment of recurrent refractory osteosarcoma.Method According to the treatment method,98 patients with recurrent refractory osteosarcoma were divided into general chemotherapy group and ifosfamide group,with 49 cases in each group.Patients in the general chemotherapy group were given DP regimen chemotherapy,and patients in the ifos-famide group were combined with ifosfamide chemotherapy on this basis.The tumor markers[tumor specific growth fac-tor(TSGF),vascular endothelial growth factor(VEGF),rat sarcoma oncogene(RAS),and erb-b2 receptor tyrosine kinase 3(ERBB3)],limb function,sleep quality,clinical efficacy and adverse reactions were compared between the two groups.Result After treatment,the TSGF,VEGF,RAS and ERBB3 levels after treatment in the two groups were lower than those before treatment(P<0.05),and the levels of TSGF,VEGF,RAS and ERBB3 in the ifosfamide group were lower than those in the general chemotherapy group(P<0.05).After treatment,the Harris scale scores of the two groups of pa-tients were significantly higher than that of the group before treatment(P<0.01),and the Pittsburgh sleep quality index(PSQI)was significantly lower than that of the group before treatment(P<0.01).In addition,the Harris scale scores of the ifosfamide group was significantly higher than that of the general chemotherapy group(P<0.01),and the PSQI score was significantly lower than that of the general chemotherapy group(P<0.01).The effective rate of treatment in the ifos-famide group was 46.94%,which was higher than 22.45%in the general chemotherapy group(P<0.05),and the total ad-verse reaction rate was 6.12%,which was significantly lower than the 28.57%in the general chemotherapy group(P<0.01).Conclusion Ifosfamide combined with DP regimen in the treatment of relapsed refractory osteosarcoma can effec-tively inhibit the development of tumor cells,control the condition,promote the recovery of limb function,and impr
作者
张松勤
井小会
赵广辉
潘秀琴
ZHANG Songqin;JING Xiaohui;ZHAO Guanghui;PAN Xiuqin(Department of Orthopaedic,Pingdingshan First People’s Hospital,Pingdingshan 467000,He’nan,China;Department of Oncology,Pingdingshan First People’s Hospital,Pingdingshan 467000,He’nan,China)
出处
《癌症进展》
2021年第14期1477-1480,共4页
Oncology Progress
